The ADA’s 85th Scientific Sessions, taking place June 20–24 in Chicago, promise to mark a turning point in diabetes and obesity care. With a slate of late-breaking data releases, the spotlight is firmly on next-generation weight-loss treatments and transformative technologies in type 1 diabetes (T1D) management. Obesity: From Weekly to Monthly Dosing, and Beyond A major focus is on evolving weight-loss therapies that push beyond traditional GLP-1 receptor agonists (RAs). Highlights include: CagriSema (Novo Nordisk): A novel dual-agonist therapy combining semaglutide with cagrilintide (amylin + calcitonin RA). This “multi-angle” approach could raise the ceiling on safe, effective weight loss. MariTide…
Author: Abhay Panchal
Updated quality indicators for endoscopic ultrasound, published by the American Society for Gastrointestinal Endoscopy and the American College of Gastroenterology, reflect profound innovations that have occurred in the field in recent years, particularly the rise of interventional and therapeutic EUS, which did not exist when the previous esophagogastroduodenoscopy quality indicators were published in 2015. Lead author Girish Mishra, MD, the gastroenterology and hepatology section chief at Wake Forest University School of Medicine, in Winston-Salem, N.C., told Gastroenterology & Endoscopy News that because the field of interventional EUS has emerged only within the last decade, the new quality indicators reflect the…
In a groundbreaking peer-reviewed study published in Cureus, gastroenterologist Dr. Adewale Ajumobi and co-author Akash Patel evaluated the reliability of ChatGPT-4 in offering pre-colonoscopy instructions. The research posed 25 patient-style questions to ChatGPT, covering bowel prep, medication adjustments, and dietary guidelines—critical areas where patient confusion often derails procedures. The results? ChatGPT-4’s responses aligned 100% with clinical guidelines from leading global medical societies, including ESGE, USMSTF, ACG-CAG, ASGE, ACC-AHA, and ADS. It consistently recommended appropriate timing, prep steps, and medication protocols, demonstrating its potential as a dependable digital educator for GI patients.
On June 25, 2025, Google DeepMind introduced AlphaGenome, a powerful AI model designed to interpret the human genome with unprecedented accuracy. AlphaGenome predicts how DNA mutations affect gene regulation by processing up to 1 million DNA base pairs at single-letter resolution—a significant leap in both scale and granularity compared to previous models like Enformer. This new model can forecast a broad range of biological phenomena: from where genes start and end, to RNA splicing patterns, chromatin accessibility, and protein binding. It does so across hundreds of cell types and tissues using data from leading genomic databases like ENCODE and GTEx.…
Across the country, gastroenterologists are grappling with seismic changes in care delivery — from staffing shortages and evolving screening guidelines to declining reimbursement and payer dynamics. Becker’s spoke with five gastroenterology leaders about the trends shaping their practices today.
Functional beverages are redefining the wellness market, with brands like Poppi and Olipop at the forefront of a $10 billion gut health movement. These drinks—marketed as prebiotic sodas—promise benefits like better digestion and improved energy, though scientific backing remains sparse. Poppi uses minimal apple cider vinegar and relies heavily on vibrant branding and celebrity endorsements to appeal to wellness-conscious consumers. Olipop takes a more clinical tone, offering 9g of fiber and botanical extracts, yet still operates in a gray zone when it comes to health claims.
In a significant industry move, major U.S. insurers—including UnitedHealthcare, Cigna, CVS Health, and Humana—have voluntarily pledged to streamline the prior authorization (PA) process. Announced by AHIP, the reforms aim to reduce administrative burdens and improve timely access to care. Six key commitments include:
In a timely commentary, Dr. Jane Zhu explores the evolving impact of private equity (PE) ownership in gastroenterology—a specialty now seeing over 1 in 8 practices under PE control. The piece reflects on new findings by Arnold et al., who examined colonoscopy pricing and quality following PE acquisitions in commercially insured settings. Key insights: Utilization Increases: PE-acquired practices saw more colonoscopies per physician and more unique patients—raising the question of whether PE drives patient volume or rides pre-existing trends. Pricing Trends: PE ownership was associated with a 4.5% increase in colonoscopy prices—rising to 6.7% in markets with higher PE penetration.…
A new study published in Clinical Gastroenterology and Hepatology confirms the real-world impact of ColoSense®, Geneoscopy’s FDA-approved multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening. The modeling study, titled “Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia,” assessed five CRC screening strategies—including ColoSense, FIT, blood-based tests, and mt-sDNA tests—using a 10-year Markov model simulating disease progression in average-risk adults aged 45 and older. At a real-world adherence rate of 60%, ColoSense significantly outperformed its peers in reducing CRC mortality:
A research team from the Institute for Cancer Research (ICR) and Queen Mary University of London has developed a breakthrough method to predict how colorectal cancer (CRC) cells become resistant to chemotherapy — a major reason treatment eventually fails. The method, published in Nature Communications, is called Evolutionary Informed Resistance Assays (EIRAs). It combines genetic lineage tracing with mathematical modeling to track how CRC cells evolve under the pressure of the commonly used chemotherapy drug 5-fluorouracil (5-Fu).Unlike traditional approaches that detect resistance only after it arises, EIRAs can forecast resistance trajectories. In their study, two CRC cell lines (SW620 and…